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Summary 
Contrary to expectations based on in vitro  experiments,  we previously found that pancreatic 
IL-10 did not inhibit autoimmune diabetes but accelerated it in an MHC-dependent manner. 
Therefore, the ability of IL-10 to overcome the absence of all non-MHC diabetes susceptibility 
(Idd) alleles  was studied in transgenic mice expressing pancreatic IL-10 backcrossed to BIO.H2e7 
congenic mice,  which  have  no  Idd alleles  other  than  NOD  MHC  (1-12"7). IL-10 transgenic 
backcross 1 (BC1)  mice with H2gT/e 7 haplotype devdoped dear-cut insulitis  and diabetes,  but 
neither transgenic mice with the H2g/b haplotype nor nontransgenic BC1 mice did so. Further 
implicating IL-10 in autoimmune diabetes,  anti-IL-10 antibody treatment inhibited the devel- 
opment of insulifis in NOD  mice. These results suggest that IL-10 may be necessary and suffi- 
cient for producing autoimmune diabetes in conjunction with NOD  MHC homozygosity and 
that some Idd genes may be related to the regulation of IL-10. 
I 
'L-10 is produced mainly by Th2 cells,  macrophages, and 
.Lyl +  B lymphocytes (1,  2). IL-10 inhibits Thl  cell pro- 
liferation and cytokine production in the presence of mac- 
rophages by blocking costimulatory activity in vitro (3,  4). 
These results suggest that IL-10 is a potential agent for the 
treatment  of autoimmune  diseases  or allograft rejection in 
vivo. However, experiments using transgenic mice express- 
ing IL-10 in pancreatic  13- (Ins-IL-10 mice)  or a-cells and 
their  offspring  from  backcrosses  to  NOD  mice  demon- 
strated  that  pancreatic  IL-10  did  not  inhibit  but,  instead, 
accelerated  autoimmune  diabetes  in  an  MHC-dependent 
manner (5-7).  Furthermore,  results from the backcross ex- 
periment suggested that pancreatic  IL-10 might overcome 
the absence of NOD  homozygosity at a substantial number 
of non-MHC diabetes-susceptibility (Idd) loci (6).  The ex- 
periments  described in this report were undertaken  to de- 
termine  whether  pancreatic  IL-10  is  able  to  replace  all 
known non-MHC  Idd alleles  in NOD  mice and whether 
IL-10 is sufficient for the development ofautoimmune dia- 
betes in the  transgenic  mouse model when an appropriate 
MHC  is  provided.  In  addition,  the  role  of IL-10  in  the 
pathogenesis of natural autoimmune diabetes in NOD  mice 
was studied. 
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Materials and Methods 
Animals.  Ins-IL-10 mice of the C57BL/6 background were 
derived by repeated backcrossing oflns-IL-10 mice (8) to C57BL/6 
mice (B6.Ins-IL-10 mice).  Neither insulitis nor diabetes was ob- 
served  in B6.Ins-IL-10 mice  or the  original  Ins-IL-10 mice of 
BALB/c background (8). After four backcross  generations,  these 
mice were subsequently bred with B10.H2g  7 congenic mice that 
have NOD MHC (H2g  7) but no other NOD-derived Idd alleles 
(9).  IL-10-transgenic  F1  mice  were  backcrossed  to  B10.H2  g7 
twice to derive IL-10-positive backcross  1 (BC1)  mice that were 
homozygous for  the  NOD  MHC  but  without  other  NOD- 
derived Idd alleles: BC1 [FI(B6.Ins-IL-10  X B10.H2eT) X B10.H2g  7] 
(Fig.  1).  In another set  of breedings,  IL-10-transgenic F1  mice 
were bred with NOD mice to derive F1 X NOD mice: [FI( B6.Ins- 
IL-10 X B10.H2eT) X NOD]. F1  X NOD mice were heterozy- 
gous at all non-MHC Idd loci (Fig. 1). 
The incidence of diabetes was determined by weekly measure- 
ment of blood glucose starting  at 5 wk and lasting up to 3 mo of 
age.  Diabetes was  defined as a single  non fasting blood glucose 
level over 300 mg/dl or two consecutive measurements over 230 
mg/dl in ocular blood samples tested with a Glucometer 3 (Miles 
Inc., Elkhart,  IN). 
MHC  typing was  done  by PCR  amplification  of the  I-A~ 
chain (primers,  CTCTTCAGGCTGGGATGCTCCACAT and 
TGTCTTTTCTGTCACCCTAGAACAG) followed by Mspl 
digestion.  The  amplified  material  from  homozygous  (H2g7/g  7) 
mice was not cut with Mspl, yielding a single  fragment of 282 
bp. That from heterozygous (H2g  7/b) mice contained 282-, 149-, 
and 133-bp fragments. 
mAb Treatment.  mAbs were  produced by making ascites in 
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linearized expression vectors harboring bacteriophage promoters. 
The riboprobes were hybridized to  5  bLg of each R.NA sample 
and control ttLNA. The protected RNA  hybrid and the respec- 
tive probes were analyzed on a 8% polyacrylamide gel. The signal 
was quantified using x-ray densitometry and standardized against 
the band intensity of a control probe (GAPDH). 
Immunohistochemistry.  Acetone-fixed fresh frozen sections were 
incubated with anti-B220 (PharMingen, San Diego, CA), anti-CD4 
(PharMingen), anti-CD8 (PharMingen) or anti-Mac-1 (Boehringer 
Mannheim, Indianapolis, IN) Ab. Incubation with an appropriate 
biotinylated secondary Ab (Vector Laboratories, Burlingame, CA), 
and then with avidin-biotin-peroxidase  complex (Vector Labora- 
tories)  followed.  After  color  reaction  with  diaminobenzidine 
(Sigma),  the sections were counterstained with methyl green. 
Figure 1.  Ins-lL-10 mice of the C57BL/6 background (B6.Ins-IL-10) 
were derived by repeated backcrossing  to C57BL/6 mice. They were bred 
with B10.H2  r  mice, and transgenic  F1 mice  were backcrossed  to B10.H2  g7 
mice to  derive transgenic mice  that were  homozygous for the  NOD 
MHC (H2  ~7/g7) but had no other NOD-derived Idd alleles (BC1). Tram- 
genic F1 mice were also bred with NOD mice to derive mice homozy- 
gnus for the  NOD  MHC  but heterozygous at all non-MHC  Idd loci 
(F1 ￿  NOD). The immunogenic significance  of the F1 ￿  NOD breed- 
ing experiment is similar to that of the B10.H2  .7 backcross experiment, 
because all ldd alleles  of NOD defined in previous backcross  studies were 
either recessive  or dominant with very low penetrance. 
SCID mice or nude mice with injections of 5  ￿  106 SXC-1  or 
JES5-2A5.11  hybridoma cells  given  1 wk  after pristane  (Sigma 
Chemical  Co.,  St.  Louis,  MO)  injection.  Protein  was  purified 
from the ascites by using 2-step ammonium sulfate precipitation, 
and Ig level was  quantified with a Bradford protein assay. Anti- 
IL-10 mAb of the rat IglVl (1  ~g/injection) or rat IgG class (0.5 
p~g/injection) was  administered to the experimental group three 
times a week. Control mice were treated with either PBS or rat 
IgG (Sigma).  Scoring ofinsulitis was done by examining 2 H&E- 
stained slides taken from different sites of one pancreatic block. If 
the  number  of islets  was  below  10  in both  samples,  one  more 
slide was prepared from a  different site. The  degree of insulitis 
was  classified into three categories: no insulitis, periinsulitis with 
or without minimal lymphocytic infiltration into the islets,  and 
insulitis. 
The Chi-square test was employed for statistical analysis. 
RNase Protection Assay.  Splenic P,  NA was  isolated 4  h  after 
i.p. injection of 350 p~g LPS (Sigma) by mechanical homogeniza- 
tion in guanidium thiocyanate solution and acid-phenol extraction. 
Results  and Discussion 
Before 3  mo of age, 8  of 19  IL-10-positive H297/r 7 BC1 
mice (42%) became diabetic (Table 1).  If fact, most of them 
developed diabetes before 2 mo of age, with no apparent dif- 
ference in incidence according to  sex.  In contrast,  neither 
transgenic BC1  mice with  H2g v/b haplotype  (n  =  14)  nor 
nontransgenic BC1  mice  (H2g 7/g7,  n  =  16;  H2g 7/b, n  =  17) 
ever developed diabetes during this period. Histopatholog- 
ical examination revealed clearcut insulitis in the pancreata 
of IL-10-transgenic  mice  with  the  H2g7/g  7 haplotype,  re- 
gardless of the presence  of diabetes (61%  of the total islets 
examined at the time of diabetes onset or at 3  mo  of age) 
(Fig. 2, A  and B). Most pancreatic islets of IL-10-transgenic 
mice with the H2g  7/b haplotype showed periinsulitis charac- 
teristic  of Ins-IL-10 mice  of BALB/c  or  C57BL/6  back- 
ground (8) (Fig. 2  C), and occasional islets showed minimal 
lymphocytic infiltration but without islet destruction. Pan- 
creatic islets of nontransgenic  mice  of both  MHC  haplo- 
types were free from periinsulitis or insulitis. To determine 
whether autoimmunity accounted for the  diabetes and in- 
sulitis  observed  here,  we  transplanted  neonatal  B10.H2  g7 
pancreata  into  diabetic  or  nondiabetic  male  IL-10-trans- 
genic BC1  mice of the H2  g7/g7 haplotype. As a  result, mas- 
sive lymphocytic infiltration with  abortive islet formation 
was observed in all pancreatic grafts 3-4 wk after transplan- 
tation (n  =  3)  (Fig. 2 E), whereas control grafts placed into 
the  nontransgenic  BC1  mice  of  the  H2  g7/,e7  haplotype 
formed mature islets, with only very rare inflammatory cells 
(n  =  3)  (Fig. 2  D).  The  results from  the graft experiment 
and  strict  dependence  of diabetes  on  NOD  MHC  ho- 
mozygosity indicate that autoimmunity was indeed respon- 
Table 1.  The Incidence of Diabetes in BIOH.2g7 BC1  and FIX  NOD  Mice Over a 3-too Observation Period 
B10.H2~ 7 BC1  F1  X NOD 
IL-10 transgenic  Nontransgenic  IL-10 transgenic  Nontransgenic 
H2  gT/t'  H2eV/~  H2g7/,e  7  H2  r  H2,e7/,~  7  H2,e  7/I'  H2r  '7  H2a  '7/1' 
8/19 (42%)  0/14  0/16  0/17  7/13  (54%)  0/14  0/12  0/16 
2664  IL-10 and Autoimmune Diabetes Figure 2.  Pancreatic  sections from an 8-wk-old diabetic (A) and a 
3-too-old nondiabetic (t3) IL-10-transgenic  BC1 mouse of  the H.287/g7 hap- 
lotype show insulitis with islet destruction (￿  (C) The pancreas from 
a 3-mo-old BC1 mouse of the H2  gT/~ haplotype shows periinsulitis char- 
acteristic of Ins-IL-10 mace but not insulitis (￿  (D) A control graR 
of  the neonatal B10.H2g7 pancreas into a male nontransgenic  B10.H2  gT/g7 
BC1 mouse shows mature islets with very rare inflammatory  cells (X400). 
(E) A graft from the neonatal B10.H2g7 pancreas under the kidney cap- 
sule of a male transgenic B10.H2g7/g7 BC1 mouse (￿  Massive infil- 
tration of lymphocytes and abortive islet formation were observed 4 wk 
after transplantation. (F) Insulitis with islet destruction was also observed 
in the pancreas of  an 8-wk-old transgenic F1 ￿  NOD mouse of  the H.2  g7/~7 
haplotype (￿ 
sible  for  the  islet  destruction  in  IL-10-transgenic  H2  g7/g7 
BC1  mice.  Together,  these  results  suggest  that pancreatic 
IL-10 can overcome the absence of all non-MHC Icld alleles 
described in NOD mice. In other words, IL-10 may be suffi- 
cient for autoimmune diabetes  if NOD  MHC  homozygos- 
ity is provided. 
Idd genes revealed in backcross studies  should be reces- 
sive or dominant with very low penetrance.  Thus,  the re- 
sult from the F1  ￿  NOD  breeding experiment should tell 
if pancreatic IL-10 can overcome the absence (actually het- 
erozygosity) of all non-MHC Icld alleles  described in NOD 
mice like the B10.H2~ 7 backcross study. 7  of 13 transgenic 
H2  g7/g7 F1  ￿  NOD  mice  (54%)  became  diabetic  before  3 
mo of age  (Table  1).  Yet,  transgenic  F1  ￿  NOD  mice of 
the H2g7/b haplotype  or nontransgenic  F1  X  NOD  mice 
never became diabetic  during this period.  Histopathologi- 
cal  examination  again  revealed  insulitis  with  islet  destruc- 
tion in  transgenic  F1  X  NOD  mice of the H297/g7 haplo- 
type  (65%  of the  total  islets  examined)  but  not  in  other 
three combinations (Fig. 2  F). That the incidence of diabe- 
tes was less  than  100% in both B10.H2  .7 BC  1 and  F1  X 
NOD  mice might be attributed to the fact that only 10% of 
total islet cell mass would be sufficient for glucose homeo- 
stasis  and  that the  observation  period  was relatively short. 
Some  environmental  factor(s)  might also be  involved,  re- 
sulting in diabetes  in some but not all  mice,  similar to the 
NOD  parental  strain.  In contrast to these  results,  systemic 
IL-10 administration  reportedly decreased the incidence of 
diabetes  in  NOD  mice  (10).  This  discrepancy  might  be 
caused by the different site of cytokine administration  (sys- 
temic  vs.  local),  which  was  most  clearly demonstrated  in 
case of TGF-I31 (11). Additionally, the time point of IL-10 
administration was 10 wk of age in the study involving sys- 
temic  administration  (10),  which  is  much  later  than  that 
experienced by Ins-IL-10 mice (8). 
The mechanism  of IL-10-induced autoimmunity is  not 
clearly understood.  Transgenic  production  of IL-10 leads 
to induction of adhesion molecules and periislet inflamma- 
tion  (8).  However,  effects  attributable  to  nonspecific  in- 
flammation or increased  chemotaxis  alone  cannot account 
for  the  IL-10-mediated  induction  or  acceleration  of au- 
toimmune  diabetes  observed  in  our  mice.  For  instance, 
pancreatic  IFN-',/ did not accelerate  autoimmune  diabetes 
in  our  backcross  experiments  to  NOD  mice,  although 
IFN-"/  transgene  expression  induced  pronounced  pancre- 
atic  inflammation  (data  not  shown).  Likewise,  pancreatic 
expression of TNF-c~ elicited insulitis  but did not acceler- 
ate diabetes in NOD  background (Flavell, R.A.  1995.  Ge- 
netic  manipulation  of cytokine  expression  in  the  study of 
autoimmunity  and  asthma.  The  34th  Midwinter  Confer- 
ence  of Immunologists,  Pacific  Grove,  CA).  Our  results 
also  differed  from  those  from  an  RIP-IL-2  backcross  to 
NOD  mice  in  which  IL-2  transgene  expression  did  not 
overcome the  absence  of a  single  copy of the  Idd3-IddlO 
segment (12),  while  IL-10 expression  could overcome the 
absence  of all  non-MHC  Idd  alleles.  Furthermore,  in  our 
separate  breeding experiment  using another strain  of con- 
genic  mice  (NOD.B6PL-Thyla-Idd3-IddlO),  transgenic 
IL-10 specifically overcame the  absence  of the  Idd3-IddlO 
segment  (Lee,  M.-S.,  L.S.  Wicker,  L.B.  Peterson,  and N. 
Sarvetnick,  unpublished  data).  The  effect of IL-10 in  our 
model  might be  related  to  a  shift in  the balance between 
Thl/Th2  responses  by  IL-10,  and  a  Th2-dominant  re- 
sponse may not inhibit the autoimmune destruction of tar- 
get  tissue,  contrary  to  previous  belief (13).  For  instance, 
anti-B7-1  treatment  has  been  reported  to  induce  Th2- 
dominant  responses  in  vivo  (14),  yet  the  same  treatment 
accelerated  autoimmune  diabetes  in  NOD  mice  (15). 
However,  transgenic  expression  of IL-4 in  the  pancreatic 
[3-islet  cells did not accelerate autoimmune diabetes in our 
backcross experiment to NOD  mice (data not shown).  The 
discrepancy between IL-4 and IL-10 transgenic NOD mice 
suggests that the effects of  local IL-10 might not be directly 
related  to  the  Thl/Th2  balance.  Thus,  IL-10-induced or 
IL-10-accelerated autoimmune  diabetes  may entail  an un- 
expected immunological mechanism. Activation ofB lym- 
phocytes by IL-10 leading to proliferation  and Ig produc- 
tion  has  been  reported  (16-18),  IL-10  may  enhance  the 
antigen-presenting  function  of B  lymphocytes as  well  re- 
2665  Lee et al.  Brief Definitive Report Figure 3.  lmmunohistochemistry  revealed a prominent B lymphocyte 
infiltrate stained with anti-B220 antibody (A) and also a substantial num- 
ber of CD4 + T lymphocytes (/3) in pancreatic sections from a transgenic 
BC1 mouse of the H2e  7~7 haplotype (￿  Mac-1  + macrophages  and a 
small number ofCD8  § cells were also present. 
sulting in diversification ofT cell responses through B lym- 
phocytes functioning as APC as suggested in SLE (19, 20). 
Increased MHC  class  II expression  on B  lymphocytes by 
IL-10 might be  related  to the  enhanced antigen  presenta- 
tion by B  lymphocytes (21).  Consistent with  this,  B  lym- 
phocytes  stained  with  anti-B220  antibody  were  the  pre- 
dominant cells infiltrating the pancreata oftransgenic H2  gT/g7 
BC1  and  F1  ￿  NOD  mice  as  revealed  by  immunohis- 
tochemistry  (Fig.  3  A).  CD4 +  T  lymphocytes  were  the 
next  most abundant  cells  (Fig.  3  B),  followed by Mac-1 + 
macrophages and a small number of CD8 + T  lymphocytes 
(data not shown). 
The  foregoing outcomes with  our  transgenic  mice  did 
not indicate a role for IL-10 in the development of natural 
autoimmune  diabetes  in NOD  mice.  To address this  issue 
and  to learn  if IL-10 is  necessary for natural  autoimmune 
diabetes, we administered anti-IL-10 Ab to NOD  mice and 
compared the  severity  of insulitis  between  treated  groups 
and control groups. In female NOD  mice treated for 6 wk 
starting at 3-4 wk of age (n  =  12), the proportion of islets 
showing  insulitis  was  significantly  lower  than  in  control 
NOD mice treated with PBS or rat IgG (n =  10) (P <0.001) 
(Table 2 A). In another experiment,  anti-IL-10 was admin- 
istered  for 3  mo  starting  when  the  mice  were  3  wk  old. 
Again, virtually no insulitis was observed in their pancreata, 
whereas insulitis was pronounced in control mice (Table 2 
B). This result concurs with the ability of anti-IL-10 to delay 
the onset of autoimmunity in NZB/W  (22)  and indicates a 
larger role  for IL-10 in  a  broad spectrum  of autoimmune 
disorders.  These  effects might be  related  to  the  change  in 
TNF-0~ level by anti-IL-10 as was suggested in the study in- 
volving NZB/W  mice; however,  regardless  of the presence 
of secondary mediators of IL-10, the results suggest an im- 
portant role for IL-10 in the pathogenesis of autoimmunity. 
Yet,  our results  contrast with a report  showing no change 
in the incidence of diabetes by anti-IL-10 administration to 
NOD  mice (10). However, the NOD  mice in that experi- 
ment were 10 wk old, a time when effector T  lymphocytes 
are already sensitized to a variety of islet antigens  (23,  24). 
If IL-10 is involved in the pathogenesis of autoimmune di- 
abetes,  the  critical  point would be  the  initial  sensitization 
phase by APC, not the effector phase mediated by T  lym- 
phocytes.  If this hypothesis is correct,  abrogation of IL-10 
after  establishment  of autoimmunity  might  not  affect  the 
clinical course of diabetes. 
The  above  results  suggest  that  IL-10 may be  necessary 
and sufficient for the development of autoimmune diabetes 
in conjunction with  NOD  MHC  homozygosity, and  also 
that some uncharacterized  non-MHC  Idd alleles  of NOD 
mice may be  related  to  abnormal production  of IL-10 or 
abnormal sensitivity to IL-10. To examine whether  IL-10 
regulation differs in NOD and diabetes-resistant mice, IL-10 
mRNA levels in their spleens were quantified after LPS ad- 
ministration by using RNase protection assays. Our prelim- 
inary results indicated that the ratio of the IL-10 signal to the 
control (GAPDH)  signal was higher in a 5-mo-old female 
NOD  mouse  (124%)  and a 7-wk-old female NOD  mouse 
(97%)  compared  to  that  in  a  7-wk-old  female  BALB/c 
(23%)  and  in  a  7-wk-old  female  C57BL/6  mouse  (21%). 
On the  other hand,  the TNF-0t  signal  normalized  for the 
control signal was highest in the BALB/c mouse (74%), in- 
termediate in the C57BL/6 mouse (47%), and lowest in the 
5-mo-old and 7-wk-old NOD  mice (both 26%). This pre- 
liminary  result  in  mice  is  consistent  with  increased  IL-10 
production  in  humans  with  SLE,  rheumatoid  arthritis  or 
Sjogren's syndrome, suggesting a role for IL-10 regulation 
not only in autoimmune  diabetes  but in a broad spectrum 
of autoimmune  diseases  (25).  The  inverse  relationship  be- 
tween IL-10 and TNF-ix signals might relate to the inhibi- 
tion of TNF-0t expression by IL-10 (22,  26).  Moreover,  a 
relationship  has been proposed between  low TNF-o~ pro- 
Table 2.  Histological  Analysis of lsletsfiom  Anti-IL-10 and 
Control-treated NOD Mice 
A. No. of Islets*  B. No. of Islets* 
Peri-  Peri- 
Normal  insulitis  Insulitis  Normal  insulitis lnsulitis 
Anti-IL-10  187  14  1  51  15  2 
Control  84  57  38  27  44  70 
*Effect of anti-IL~10 treatment for 6 wk on insulitis in NOD mice 
starting at 3-4 wk of age. 
IL-10 mAb was administered to the  experimental group  (n  =  12), 
while control mice (n =  10) were treated with either PBS or rat lgG. 
The experimental group had a significantly  lower proportion of insulitis 
and periinsulitis. 
*Effect of anti-IL-10 treatment for 3 mo starting at 3 wk of age. Anti- 
IL-10 was given to female NOD mice (n =  5), while rat lgG or PBS 
was given to control mice (n =  8). Again, anti-IL-]0 treatment inhib- 
ited the development of insulitis almost completely. 
2666  IL-10 and Autoimmune Diabetes duction itself and the development of autoimmune diseases 
(27,  28).  The susceptibility to autoimmunity in mice with 
low  TNF-et  production  could be  a  consequence  of their 
high IL-10 production. 
Together,  these results  strongly suggest a role for IL-10 
in the pathogenesis  of autoimmune diabetes in both trans- 
genic mice and NOD  mice. Previous experiments demon- 
strating the inhibitory activity of IL-10 were performed in 
vitro  using  defined  subsets  of cells.  Immune  responses  in 
vivo  involve  several  APC  such  as  dendritic  cells,  macro- 
phages  and  B  lymphocytes,  and  their  interactions  with 
CD4 § and CD8 § T  lymphocytes in which many signals are 
delivered from one cell to another.  Thus, in vivo effects of 
IL-10 may be different from in vitro findings.  B  lympho- 
cytes differ from other APCs in that they can concentrate 
specific  proteins  with  their  surface  Ig  and  present  even 
nondominant  determinants  to  T  lymphocytes,  leading  to 
diversification  of T  cell  responses  probably after  initial  T 
cell  priming  to  immunodominant  determinants  by  den- 
dritic cells  (29).  Previous work has demonstrated the exis- 
tence  of low-affinity autoreactive  T  lymphocytes escaping 
from thymic censorship  (30, 31).  Thus, we are tempted to 
speculate that B lymphocytes stimulated by IL-10 in NOD 
mice would activate those T  lymphocytes reactive to a va- 
riety  of subdominant  or cryptic determinants  of self anti- 
gens, resulting in diversified T  cell responses. A  role for B 
lymphocytes in the  development  of autoimmune  diabetes 
in NOD  mice was suggested in an experiment showing ab- 
rogation  of diabetes  by anti-IgM administration  (32).  This 
scenario fits well with the intermolecular and intramolecular 
spreading of antigenic determinants in autoimmune diabetes 
and  experimental  allergic  encephalomyelitis  (23,  24,  33). 
Accordingly, we propose that IL:10 can affect interactions 
between B and T  lymphocytes and the resultant diversifica- 
tion of T  cell responses, which are critical to the progres- 
sion to clinical autoimmune diseases. 
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